|
[1]
|
Burris KD, Molski TF,Xu C,et al. Aripipirazole,a novel antipsychotic,is a high-affinity partial agonist at human dopamine D2 receptors[J].J Pharmacol Exp Ther,2002,302:381. |
|
[2]
|
Inoue A,Nakata Y.Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy[J].Jpn J Pharmacol,2001,86:376. |
|
[3]
|
Lieberman JA.Dopamine partial agonists:a new class of antipsychotic[J].CNS Drugs,2004,18(4):251. |
|
[4]
|
Marder SR,McQuade RD,Stock E. Aripipirazole in the treatment of schizophrenia:safety and tolerability in the treatment of schizophrenia: safety and tolerability in the short-term,placebocontrolled trials[J].Schizophr Res,2003,1916:1. |
|
[5]
|
Logue DD,Gonzalez N,Heligman SD,et al.Hyperglycemia in a 7-year-old child treeyed with Aripipirazole[J].Am J Psychiatry,2007,164(1):173. |
|
[6]
|
Newcomer JW,Haupt DW. The metabolic effects of antipsychotic medications[J].Can J Psychiatry,2006,51:480. |
|
[7]
|
McQuade RD,Stock E,Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripipirazole:results from a randomized,double-blind study[J].J Clin Psychiatry,2004,65(Suppl 18):47. |
|
[8]
|
ADA.Consensus development conference on antipsychotic drugs and obesity and diabetes (American Diabetes Association; American Psychiatric Association; American Association of clinical Endocrinologists;North American Association for the study of obesity)[J].Diabetes Care,2004,27:596. |
|
[9]
|
De Hert M,Hanssens L,Winkel R, et al. A case series:evaluation of the metabolic safety of aripipirazole[J]. Schizophr,2007,33:823. |
|
[10]
|
Olfson M,Marcus SC,Corey-Lisle P,Hyperlipidemia forlowing treatment with antipsychotic medications[J].Am J Psychiatry,2006,163:1821. |
|
[11]
|
Lee BH,Kim YK,Park SH.Using aripipirazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: A pilot study Prog Neuropsychopharmacol Biol Psychiatry[J]. 2006,30:714. |
|
[12]
|
Anghelescu I,Wolf J.Successful switch to aripipirazole after induction of hyperprolactinemia by ziprasidone:a case report[J].J Clin Psychiatry,2004,65:1286. |
|
[13]
|
Hanssens L,L Italien G,Marcus R, et al. Sexual dysfunction in naturalistic,open-label study of aripipirazole and standard-of-care in community-treated patients with schizophrenia(the STAR trial)[C].Toronto,Canada: American Psychiatric Association 159th annual meeting.2006. |
|
[14]
|
Abilify Summary of Product Characteristics[C].London:Otsuka Pharmaceutical Europe Ltd;2006. |
|
[15]
|
Oosterhuis M, Van De Kraats G,Tenback D.Safety of Aripipirazole:high serum levels in a CYP2D6 mutated patient[J].Am J Psychiatry,2007,164(1):175. |
|
[16]
|
Spina E,de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review[J].Basic Clin Pharmacol Toxicol,2007,100(1):4. |
|
[17]
|
Kan JM, Carson WH, Saha AR, et al. Efficacy and safety of aripipirazole and haloperidol versus placebo in patients with schizophrenia and schizophrenia disorder[J]. JClin Psychiatry,2002,63:763. |
|
[18]
|
Keck PE, Jr, McElroy SL. Aripipirazole: a partial dopamine D2 receptor agonist antipsychotic[J].Expert Opin Investig Drugs,2003,12:655. |
|
[19]
|
De Hert M,Hanssens L,van Winkel R, et al.Reversibility of antipschotic treament-related diabetes in patients with schizophrenia:a case of switching to aripipirazole[J]. Diabetes Care,2006,29:2329. |
点击查看大图
下载:
